Onyx Biotec Ltd.
NNSE:ONYX37.00
INR
0.00
(0.00%)
ISIN
INE0WVU01018
Return %
Stock
S&P 500
1Y
-13.95
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Harsh Mahajan
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Punjab India
- IPO Date
- Nov 22, 2024
- Website
- onyxbiotec.com
- Similar Companies
- Business
- Onyx Biotec Ltd. is an India-based pharmaceutical manufacturing and contract development company that specializes in the development, production, and supply of sterile injectables, oral suspensions, and parenteral formulations. The company operates primarily as a Contract Development and Manufacturing Organization (CDMO) and third-party contract manufacturer for domestic and international pharmaceutical corporations. Its product and service portfolio comprises sterile water for injections (SWFI); dry powder injectables, including cephalosporins, penicillins, and carbapenems; liquid parenteral solutions in both small volume parenterals (SVP) and large volume parenterals (LVP); dry syrups and oral powder suspensions used across anti-infective, antibiotic, and therapeutic applications; and comprehensive contract research, testing, and regulatory documentation services. Onyx Biotec operates advanced, current Good Manufacturing Practice (cGMP)-compliant manufacturing facilities situated in Baddi, Himachal Pradesh, serving institutional clients, hospital networks, and major pharmaceutical enterprises across India as well as select international export markets. Founded in 2005 and headquartered in Panchkula, Haryana, India, the company was formerly known as Onyx Biotec Private Limited prior to its corporate restructuring. In recent operational and strategic developments, Onyx Biotec completed its initial public offering (IPO) and listed its equity shares on the National Stock Exchange of India (NSE Emerge platform) in November 2024 to fund ongoing capital expenditure and capacity expansion programs. The company has deployed capital toward upgrading its Unit I manufacturing facility in Baddi to expand large-volume parenteral capacities and modernize manufacturing infrastructure, alongside establishing advanced high-speed automated production lines for dry syrups and dry powder injectables at Unit II to support expanding contract manufacturing volumes and target international regulatory approvals across Southeast Asia, Africa, and the Middle East.